Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 5/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20411385 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2MGLLEPHX2RECQL | |
| SCHEMBL20411386 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2MGLLEPHX2RECQL | |
| SCHEMBL15776899 | 0.92 | USP2 (0.41) | USP2SMN1; SMN2MGLLEPHX2RECQL | |
| SCHEMBL368761 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2MGLLEPHX2RECQL | |
| SCHEMBL5765422 | 0.86 | USP2 (0.48) | USP2SMN1; SMN2MGLLEPHX2RECQL | |
| SCHEMBL18481140 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2MGLLEPHX2RECQL | |
| SCHEMBL16419553 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2MGLLEPHX2RECQL | |
| SCHEMBL15777271 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2EPHX2RECQLHPGD | |
| SCHEMBL21590800 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2EPHX2RECQLHPGD | |
| SCHEMBL21590661 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2EPHX2RECQLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-6699870-B2 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. | 2003-06-05 | — | — | US | disclosed |
| US-6498159-B1 | SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE | EISAI CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | USP2 4329/4885SMN1; SMN2 1922/4885MGLL 3975/4885 |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | USP2 673/4885SMN1; SMN2 1183/4885MGLL 3029/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | USP2 673/4885SMN1; SMN2 1183/4885MGLL 3029/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | USP2 4329/4885SMN1; SMN2 1922/4885MGLL 3975/4885 |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | USP2 2766/4885SMN1; SMN2 2594/4885MGLL 4682/4885 |
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CYP3A43, ABCB1, ABCB11 | USP2 3937/4885SMN1; SMN2 4066/4885MGLL 1370/4885 |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | CLIC1, CBR1, CBR3 | USP2 3351/4885SMN1; SMN2 1322/4885MGLL 3692/4885 |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | USP2 673/4885SMN1; SMN2 1183/4885MGLL 3029/4885 |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | FAAH, FAAH2, FFAR1 | USP2 503/4885SMN1; SMN2 1126/4885MGLL 246/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | USP2 4329/4885SMN1; SMN2 1922/4885MGLL 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.